• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

显性遗传阿尔茨海默病网络中家族性阿尔茨海默病的早期行为变化。

Early behavioural changes in familial Alzheimer's disease in the Dominantly Inherited Alzheimer Network.

作者信息

Ringman John M, Liang Li-Jung, Zhou Yan, Vangala Sitaram, Teng Edmond, Kremen Sarah, Wharton David, Goate Alison, Marcus Daniel S, Farlow Martin, Ghetti Bernardino, McDade Eric, Masters Colin L, Mayeux Richard P, Rossor Martin, Salloway Stephen, Schofield Peter R, Cummings Jeffrey L, Buckles Virginia, Bateman Randall, Morris John C

机构信息

1 Mary S. Easton Centre for Alzheimer's Disease Research at UCLA, 10911 Weyburn Ave., #200, Los Angeles, CA, 90095, USA

2 David Geffen School of Medicine at UCLA, Dept. of Medicine, 911 Broxton, Los Angeles, CA, 90024, USA.

出版信息

Brain. 2015 Apr;138(Pt 4):1036-45. doi: 10.1093/brain/awv004. Epub 2015 Feb 15.

DOI:10.1093/brain/awv004
PMID:25688083
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4963801/
Abstract

Prior studies indicate psychiatric symptoms such as depression, apathy and anxiety are risk factors for or prodromal symptoms of incipient Alzheimer's disease. The study of persons at 50% risk for inheriting autosomal dominant Alzheimer's disease mutations allows characterization of these symptoms before progressive decline in a population destined to develop illness. We sought to characterize early behavioural features in carriers of autosomal dominant Alzheimer's disease mutations. Two hundred and sixty-one persons unaware of their mutation status enrolled in the Dominantly Inherited Alzheimer Network, a study of persons with or at-risk for autosomal dominant Alzheimer's disease, were evaluated with the Neuropsychiatric Inventory-Questionnaire, the 15-item Geriatric Depression Scale and the Clinical Dementia Rating Scale (CDR). Ninety-seven asymptomatic (CDR = 0), 25 mildly symptomatic (CDR = 0.5), and 33 overtly affected (CDR > 0.5) autosomal dominant Alzheimer's disease mutation carriers were compared to 106 non-carriers with regard to frequency of behavioural symptoms on the Neuropsychiatric Inventory-Questionnaire and severity of depressive symptoms on the Geriatric Depression Scale using generalized linear regression models with appropriate distributions and link functions. Results from the adjusted analyses indicated that depressive symptoms on the Neuropsychiatric Inventory-Questionnaire were less common in cognitively asymptomatic mutation carriers than in non-carriers (5% versus 17%, P = 0.014) and the odds of experiencing at least one behavioural sign in cognitively asymptomatic mutation carriers was lower than in non-carriers (odds ratio = 0.50, 95% confidence interval: 0.26-0.98, P = 0.042). Depression (56% versus 17%, P = 0.0003), apathy (40% versus 4%, P < 0.0001), disinhibition (16% versus 2%, P = 0.009), irritability (48% versus 9%, P = 0.0001), sleep changes (28% versus 7%, P = 0.003), and agitation (24% versus 6%, P = 0.008) were more common and the degree of self-rated depression more severe (mean Geriatric Depression Scale score of 2.8 versus 1.4, P = 0.006) in mildly symptomatic mutation carriers relative to non-carriers. Anxiety, appetite changes, delusions, and repetitive motor activity were additionally more common in overtly impaired mutation carriers. Similar to studies of late-onset Alzheimer's disease, we demonstrated increased rates of depression, apathy, and other behavioural symptoms in the mildly symptomatic, prodromal phase of autosomal dominant Alzheimer's disease that increased with disease severity. We did not identify any increased psychopathology in mutation carriers over non-carriers during the presymptomatic stage, suggesting these symptoms result when a threshold of neurodegeneration is reached rather than as life-long qualities. Unexpectedly, we found lower rates of depressive symptoms in cognitively asymptomatic mutation carriers.

摘要

先前的研究表明,抑郁、冷漠和焦虑等精神症状是早期阿尔茨海默病的危险因素或前驱症状。对有50%遗传常染色体显性阿尔茨海默病突变风险的人群进行研究,能够在注定会患病的人群出现病情进展性衰退之前,对这些症状进行特征描述。我们试图对常染色体显性阿尔茨海默病突变携带者的早期行为特征进行描述。261名不知道自己突变状态的人参加了显性遗传阿尔茨海默病网络研究,该研究针对常染色体显性阿尔茨海默病患者或有患病风险的人群,使用神经精神科问卷、15项老年抑郁量表和临床痴呆评定量表(CDR)进行评估。将97名无症状(CDR = 0)、25名轻度症状(CDR = 0.5)和33名明显受影响(CDR > 0.5)的常染色体显性阿尔茨海默病突变携带者与106名非携带者在神经精神科问卷上的行为症状频率以及老年抑郁量表上的抑郁症状严重程度方面进行比较,采用具有适当分布和连接函数的广义线性回归模型。调整分析结果表明,神经精神科问卷上的抑郁症状在认知无症状突变携带者中比在非携带者中更少见(5%对17%,P = 0.014),认知无症状突变携带者出现至少一种行为体征的几率低于非携带者(优势比 = 0.50,95%置信区间:0.26 - 0.9S,P = 0.042)。与非携带者相比,轻度症状突变携带者中抑郁(56%对17%,P = 0.0003)、冷漠(40%对4%,P < 0.0001)、脱抑制(16%对2%,P = 0.009)、易怒(48%对9%,P = 0.0001)、睡眠改变(28%对7%,P = 0.003)和激越(24%对6%,P = 0.008)更为常见,且自评抑郁程度更严重(老年抑郁量表平均得分2.8对1.4,P = 0.006)。焦虑、食欲改变、妄想和重复运动活动在明显受损的突变携带者中也额外更为常见。与晚发型阿尔茨海默病的研究相似,我们证明在常染色体显性阿尔茨海默病的轻度症状前驱期,抑郁、冷漠和其他行为症状的发生率增加,且随疾病严重程度加重。我们未发现无症状阶段突变携带者的精神病理学表现比非携带者增加,这表明这些症状是在达到神经退行性变阈值时出现,而非作为终生特质。出乎意料的是,我们发现认知无症状突变携带者的抑郁症状发生率较低。

相似文献

1
Early behavioural changes in familial Alzheimer's disease in the Dominantly Inherited Alzheimer Network.显性遗传阿尔茨海默病网络中家族性阿尔茨海默病的早期行为变化。
Brain. 2015 Apr;138(Pt 4):1036-45. doi: 10.1093/brain/awv004. Epub 2015 Feb 15.
2
Clinical, pathophysiological and genetic features of motor symptoms in autosomal dominant Alzheimer's disease.常染色体显性阿尔茨海默病运动症状的临床、病理生理和遗传特征。
Brain. 2019 May 1;142(5):1429-1440. doi: 10.1093/brain/awz050.
3
Relationship between dementia severity and behavioural and psychological symptoms in early-onset Alzheimer's disease.早发性阿尔茨海默病中痴呆严重程度与行为和心理症状之间的关系。
Psychogeriatrics. 2015 Dec;15(4):242-7. doi: 10.1111/psyg.12108. Epub 2015 Mar 3.
4
Neuropsychiatric symptoms are early indicators of an upcoming metabolic decline in Alzheimer's disease.神经精神症状是阿尔茨海默病即将发生代谢衰退的早期指标。
Transl Neurodegener. 2021 Jan 4;10(1):1. doi: 10.1186/s40035-020-00225-y.
5
Suicidal ideation is common in autosomal dominant Alzheimer's disease at-risk persons.有自杀意念的想法在常染色体显性阿尔茨海默病高危人群中很常见。
Int J Geriatr Psychiatry. 2020 Jan;35(1):60-68. doi: 10.1002/gps.5215. Epub 2019 Oct 22.
6
Accelerated long-term forgetting in presymptomatic autosomal dominant Alzheimer's disease: a cross-sectional study.症状前常染色体显性阿尔茨海默病的加速长期遗忘:一项横断面研究。
Lancet Neurol. 2018 Feb;17(2):123-132. doi: 10.1016/S1474-4422(17)30434-9.
7
Comparison of amyloid burden in individuals with Down syndrome versus autosomal dominant Alzheimer's disease: a cross-sectional study.唐氏综合征与常染色体显性阿尔茨海默病患者淀粉样蛋白负担的比较:一项横断面研究。
Lancet Neurol. 2023 Jan;22(1):55-65. doi: 10.1016/S1474-4422(22)00408-2.
8
Neuropsychiatric symptoms and Apolipoprotein E: Associations with eventual Alzheimer's disease development.神经精神症状与载脂蛋白E:与阿尔茨海默病最终发展的关联。
Arch Gerontol Geriatr. 2016 Jul-Aug;65:231-8. doi: 10.1016/j.archger.2016.04.006. Epub 2016 Apr 14.
9
The Alzheimer's prevention initiative composite cognitive test score: sample size estimates for the evaluation of preclinical Alzheimer's disease treatments in presenilin 1 E280A mutation carriers.阿尔茨海默病预防计划综合认知测试分数:早老素1 E280A突变携带者中用于评估临床前阿尔茨海默病治疗的样本量估计
J Clin Psychiatry. 2014 Jun;75(6):652-60. doi: 10.4088/JCP.13m08927.
10
The need for a consensus in the use of assessment tools for Alzheimer's disease: the Feasibility Study (assessment tools for dementia in Alzheimer Centres across Europe), a European Alzheimer's Disease Consortium's (EADC) survey.阿尔茨海默病评估工具使用达成共识的必要性:可行性研究(欧洲各地阿尔茨海默病中心的痴呆评估工具),欧洲阿尔茨海默病协会(EADC)的一项调查。
Int J Geriatr Psychiatry. 2005 Aug;20(8):744-8. doi: 10.1002/gps.1355.

引用本文的文献

1
Hybrid multi-modality multi-task learning for forecasting progression trajectories in subjective cognitive decline.用于预测主观认知衰退进展轨迹的混合多模态多任务学习
Neural Netw. 2025 Jun;186:107263. doi: 10.1016/j.neunet.2025.107263. Epub 2025 Feb 15.
2
FORTCARE-MCI study protocol: evaluation of Fortasyn Connect in the management of mild cognitive impairment in primary care.FORTCARE-MCI研究方案:在初级保健中评估福莱思安健素对轻度认知障碍的管理作用
Front Neurol. 2024 Oct 3;15:1434210. doi: 10.3389/fneur.2024.1434210. eCollection 2024.
3
15 Years of Longitudinal Genetic, Clinical, Cognitive, Imaging, and Biochemical Measures in DIAN.糖尿病预防试验(DIAN)中15年的纵向基因、临床、认知、影像学和生化测量
medRxiv. 2024 Aug 9:2024.08.08.24311689. doi: 10.1101/2024.08.08.24311689.
4
Exploring the Genetic Landscape of Mild Behavioral Impairment as an Early Marker of Cognitive Decline: An Updated Review Focusing on Alzheimer's Disease.探索轻度行为障碍的遗传特征作为认知能力下降的早期标志物:关注阿尔茨海默病的最新综述。
Int J Mol Sci. 2024 Feb 24;25(5):2645. doi: 10.3390/ijms25052645.
5
Behavioral and Neurophysiological Implications of Pathological Human Tau Expression in Serotonin Neurons.病理性人 tau 蛋白在血清素神经元中的表达的行为和神经生理学意义。
ACS Chem Neurosci. 2024 Mar 6;15(5):932-943. doi: 10.1021/acschemneuro.3c00626. Epub 2024 Feb 20.
6
Neuropathology of patients with preclinical or early clinical Alzheimer's disease with pathogenic PSEN1_p. L392V: Comparison of advanced siblings.临床前或早期临床阿尔茨海默病患者携带致病性 PSEN1_p. L392V 的神经病理学:先证者的高级亲属比较。
Alzheimers Dement. 2024 Mar;20(3):2291-2296. doi: 10.1002/alz.13675. Epub 2024 Jan 12.
7
Longitudinal clinical, cognitive and biomarker profiles in dominantly inherited versus sporadic early-onset Alzheimer's disease.显性遗传与散发性早发型阿尔茨海默病的纵向临床、认知和生物标志物特征
Brain Commun. 2023 Oct 18;5(6):fcad280. doi: 10.1093/braincomms/fcad280. eCollection 2023.
8
Integrated Transcriptomics and Network Analysis Identified Altered Neural Mechanisms in Frontal Aging Brain-Associated Alzheimer's Disease.整合转录组学和网络分析鉴定出与额颞叶痴呆相关的老化大脑中改变的神经机制。
Biochem Genet. 2024 Aug;62(4):2382-2398. doi: 10.1007/s10528-023-10549-9. Epub 2023 Nov 7.
9
Depressive symptoms and hippocampal volume in autosomal dominant Alzheimer's disease.常染色体显性阿尔茨海默病患者的抑郁症状与海马体积。
Alzheimers Dement. 2024 Feb;20(2):986-994. doi: 10.1002/alz.13501. Epub 2023 Oct 14.
10
Association Between Self- and Proxy-Reported Depression and Quality of Life in Mild-Moderate Alzheimer's Disease.轻度至中度阿尔茨海默病患者自我报告与他人代报的抑郁症状与生活质量之间的关联
Am J Geriatr Psychiatry. 2024 Jan;32(1):58-67. doi: 10.1016/j.jagp.2023.08.004. Epub 2023 Aug 24.

本文引用的文献

1
Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis.常染色体显性阿尔茨海默病的症状发作:一项系统综述和荟萃分析。
Neurology. 2014 Jul 15;83(3):253-60. doi: 10.1212/WNL.0000000000000596. Epub 2014 Jun 13.
2
Subjective cognitive concerns and neuropsychiatric predictors of progression to the early clinical stages of Alzheimer disease.主观认知担忧与阿尔茨海默病早期临床阶段进展的神经精神预测因素
Am J Geriatr Psychiatry. 2014 Dec;22(12):1642-51. doi: 10.1016/j.jagp.2014.02.007. Epub 2014 Feb 26.
3
A novel PSEN1 mutation (I238M) associated with early-onset Alzheimer's disease in an African-American woman.一名非裔美国女性中与早发性阿尔茨海默病相关的新型PSEN1突变(I238M)。
J Alzheimers Dis. 2014;40(2):271-5. doi: 10.3233/JAD-131844.
4
Depressive symptoms predict cognitive decline and dementia in older people independently of cerebral white matter changes: the LADIS study.抑郁症状可预测老年人认知能力下降和痴呆,与脑白质改变无关:LADIS 研究。
J Neurol Neurosurg Psychiatry. 2013 Nov;84(11):1250-4. doi: 10.1136/jnnp-2012-304191. Epub 2013 May 28.
5
Alzheimer's disease pathology does not mediate the association between depressive symptoms and subsequent cognitive decline.阿尔茨海默病病理学不能介导抑郁症状与随后认知能力下降之间的关联。
Alzheimers Dement. 2013 May;9(3):318-25. doi: 10.1016/j.jalz.2011.11.009. Epub 2012 Nov 13.
6
Developing an international network for Alzheimer research: The Dominantly Inherited Alzheimer Network.建立阿尔茨海默病研究国际网络:显性遗传性阿尔茨海默病网络。
Clin Investig (Lond). 2012 Oct 1;2(10):975-984. doi: 10.4155/cli.12.93.
7
Clinical and biomarker changes in dominantly inherited Alzheimer's disease.常染色体显性遗传阿尔茨海默病的临床和生物标志物变化。
N Engl J Med. 2012 Aug 30;367(9):795-804. doi: 10.1056/NEJMoa1202753. Epub 2012 Jul 11.
8
Cerebrospinal fluid biomarkers and proximity to diagnosis in preclinical familial Alzheimer's disease.临床前家族性阿尔茨海默病患者的脑脊液生物标志物与接近诊断时间的相关性。
Dement Geriatr Cogn Disord. 2012;33(1):1-5. doi: 10.1159/000335729. Epub 2012 Feb 13.
9
Neuropsychiatric symptoms in Alzheimer's disease.阿尔茨海默病的神经精神症状。
Alzheimers Dement. 2011 Sep;7(5):532-9. doi: 10.1016/j.jalz.2011.05.2410.
10
Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.为了定义阿尔茨海默病的临床前阶段:来自美国国家老龄化研究所-阿尔茨海默病协会工作组关于阿尔茨海默病诊断指南的建议。
Alzheimers Dement. 2011 May;7(3):280-92. doi: 10.1016/j.jalz.2011.03.003. Epub 2011 Apr 21.